Current controversies in the management of biochemical failure in prostate cancer

Clinical Advances in Hematology and Oncology

Volumn 10, Issue 11, 2012, Pages 716-722

  Bruce, Justine Yang ^a   Lang, Joshua M ^a   McNeel, Douglas G ^a   Liu, Glenn ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Androgen deprivation therapy; Biochemical recurrence; Prostate cancer; Prostatespecific antigen

Indexed keywords

ANDROGEN; BEVACIZUMAB; BICALUTAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ANXIETY; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; BRACHYTHERAPY; COGNITIVE DEFECT; CRYOTHERAPY; ERECTILE DYSFUNCTION; FATIGUE; GYNECOMASTIA; HIGH RISK PATIENT; HOT FLUSH; HUMAN; MASTALGIA; METASTASIS FREE SURVIVAL; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SALVAGE THERAPY; SYSTEMIC THERAPY; WEIGHT GAIN;

EID: 84872746273     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society; 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-029771.pdf. Accessed October 17, 2012.
2. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910-914.
3. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol. 2003;170:S42-S46.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
5. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163-2172.
6. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000;163:1632-1642.
7. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540-545.
8. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001;165:1146-1151.
9. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
10. Swanson GP, Goldman B, Tangen CM, et al. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol. 2008;180:2453-2457.
11. Chin JL. Salvage versus adjuvant radiotherapy after radical prostatectomy: argument for adjuvant radiotherapy. Can Urol Assoc J. 2009;3:241-244.
12. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329-2335.
13. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572-578.
14. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924-2930.
15. Chade DC, Eastham J, Graefen M, et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol. 2012;61:961-971.
16. Stephenson AJ, Scardino PT, Bianco FJ Jr, DiBlasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol. 2004;172:2239-2243.
17. Chade DC, Shariat SF, Cronin AM, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011;60:205-210.
18. Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology. 1999;54:880-883.
19. Koutrouvelis P, Hendricks F, Lailas N, et al. Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three dimensional computed tomography-guided permanent pararectal implant. Technol Cancer Res Treat. 2003;2:339-344.
20. Wong WW, Buskirk SJ, Schild SE, Prussak KA, Davis BJ. Combined prostate brachytherapy and short-term ADT as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol. 2006;176:2020-2024.
21. Nguyen PL, Chen MH, D'Amico AV, et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorablerisk prostate cancer: a prospective phase 2 study. Cancer. 2007;110:1485-1492.
22. Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007;67:1106-1112.
23. Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;77:1338-1344.
24. Allen GW, Howard AR, Jarrard DF, Ritter MA. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer. 2007;110:1405-1416.
25. Pisters LL, von Eschenbach AC, Scott SM, et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997;157:921-925.
26. Benoit RM, Cohen JK, Miller RJ Jr. Cryosurgery for prostate cancer: new technology and indications. Curr Urol Rep. 2000;1:41-47.
27. de la Taille A, Hayek O, Benson MC, et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology. 2000;55:79-84.
28. Bahn DK, Lee F, Silverman P, et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer. 2003;2:111-114.
29. Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 2007;100:760-764.
30. Izawa JI, Madsen LT, Scott SM, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol. 2002;20:2664-2671.
31. Carcinoma of the prostate. Clinical trial results. The Veterans Administration Co-operative Urological Research Group. Minn Med. 1971;5:511-514.
32. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet. 1967;124:1011-1017.
33. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24:1868-1876.
34. Studer UE, Hauri D, Hanselmann S, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88. J Clin Oncol. 2004;22:4109-1418.
35. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7:472-479.
36. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171:1141-1147.
37. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004;172:S42-S46.
38. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancerspecific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
39. Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF. Continuous vs. intermittent ADT for metastatic prostate cancer. Urol Oncol. 2011 May 9. [Epub ahead of print].
40. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology. 1995;45:839-844.
41. Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of ADT for prostate cancer. Curr Opin Urol. 2004;14:177-183.
42. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164.
43. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63:742-745.
44. Akaza H, Yamaguchi A, Matsuda T, et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol. 2004;34:20-28.
45. Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010;105:1074-1081.
46. See WA, Wirth MP, McLeod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol. 2002;168:429-435.
47. McLeod DG, See WA, Klimberg I, et al. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol. 2006;176:75-80.
48. Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology. 1996;47:38-43.
49. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33:447-456.
50. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgensensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25:1596-1605.
51. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8:162-200.
52. de Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer. 2002;1:163-171.
53. Shaw GL, Wilson P, Cuzick J, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a metaanalysis of 1446 patients. BJU Int. 2007;99:1056-1065.
54. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010;57:49-59.
55. Gruca D, Bacher P, Tunn U. Safety and tolerability of intermittent ADT: a literature review. Int J Urol. 2012;19:614-625.
56. Hussain M, Tangen C, Higano C, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial. J Clin Oncol (ASCO Annual Meeting Abstracts). 2012;30(suppl): Abstract 4.
57. Moinpour C, Berry D, Ely B, et al. Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormonesensitive metastatic prostate cancer (HSM1PC)-phase III. J Clin Oncol (ASCO Annual Meeting Abstracts). 2012;30(suppl): Abstract 4571.
58. ClinicalTrials. gov. Hormone therapy in treating patients with rising PSA levels following radiation therapy for prostate cancer. http://www.clinicaltrials.gov/ct2/show/ NCT00003653?term=NCIC+PR7&rank=1. Identifier: NCT00003653. Accessed October 23, 2012.
59. ClinicalTrials. gov. Provenge with or without pTVG-HP DNA booster vaccine in prostate cancer. http://www.clinicaltrials.gov/ct2/show/NCT01706458?term=pTVGHP& rank=1. Identifier: NCT01706458. Accessed October 19, 2012.
60. ClinicalTrials. gov. A study evaluating vaccination of prostate cancer patients with self dendritic cells expressing MUC1. http://www.clinicaltrials.gov/ct2/show/ NCT00852007?term=Tn-MUC1&rank=1. Identifier: NCT00852007. Accessed October 19, 2012.
61. ClinicalTrials. gov. Androgen deprivation therapy +/-bevacizumab for PSA recurrence of prostate cancer after definitive local therapy. http://www.clinicaltrials. gov/ct2/show/NCT00776594?term=bevacizumab+AND+ADT&rank=1. Identifier: NCT00776594. Accessed October 19, 2012.
62. ClinicalTrials. gov. Study of acai juice in asymptomatic or minimally symptomatic prostate cancer patients with rising prostate specific antigen (PSA). http:// www.clinicaltrials.gov/ct2/show/NCT01521949?term=acai+PSA&rank=1. Identifier: NCT01521949. Accessed October 19, 2012.
63. ClinicalTrials. gov. Herbal therapy for treatment of recurrent prostate cancer. http://www.clinicaltrials.gov/ct2/show/NCT00669656?term=prostate+health+co cktail&rank=1. Identifier: NCT00669656. Accessed October 19, 2012.